Tredje AP fonden Reduces Stock Position in The Cooper Companies, Inc. (NASDAQ:COO)

Tredje AP fonden cut its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 50.0% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 15,439 shares of the medical device company’s stock after selling 15,438 shares during the quarter. Tredje AP fonden’s holdings in Cooper Companies were worth $1,419,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in COO. Ashton Thomas Securities LLC purchased a new position in shares of Cooper Companies during the 3rd quarter worth approximately $25,000. Byrne Asset Management LLC purchased a new position in shares of Cooper Companies during the 4th quarter worth approximately $33,000. OFI Invest Asset Management purchased a new position in shares of Cooper Companies during the 4th quarter worth approximately $34,000. Covestor Ltd grew its stake in Cooper Companies by 144.9% in the 3rd quarter. Covestor Ltd now owns 338 shares of the medical device company’s stock worth $37,000 after acquiring an additional 200 shares during the period. Finally, Brown Brothers Harriman & Co. grew its stake in Cooper Companies by 191.0% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 419 shares of the medical device company’s stock worth $46,000 after acquiring an additional 275 shares during the period. 24.39% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Wells Fargo & Company lifted their target price on shares of Cooper Companies from $115.00 to $118.00 and gave the stock an “overweight” rating in a research note on Friday, December 6th. Piper Sandler reaffirmed an “overweight” rating and issued a $115.00 target price (down from $120.00) on shares of Cooper Companies in a research note on Friday, March 7th. Citigroup lowered their target price on shares of Cooper Companies from $115.00 to $110.00 and set a “buy” rating for the company in a research note on Friday, March 7th. Needham & Company LLC reiterated a “hold” rating on shares of Cooper Companies in a report on Friday, March 7th. Finally, Robert W. Baird decreased their price target on shares of Cooper Companies from $117.00 to $107.00 and set an “outperform” rating on the stock in a report on Friday, March 7th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, Cooper Companies currently has a consensus rating of “Moderate Buy” and an average price target of $111.89.

Cooper Companies Stock Performance

NASDAQ:COO opened at $81.22 on Friday. The company has a current ratio of 1.91, a quick ratio of 1.12 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $16.21 billion, a price-to-earnings ratio of 41.65, a PEG ratio of 2.25 and a beta of 1.02. The firm’s fifty day simple moving average is $91.20 and its 200 day simple moving average is $98.86. The Cooper Companies, Inc. has a twelve month low of $77.05 and a twelve month high of $112.38.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.92. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The firm had revenue of $964.70 million for the quarter, compared to the consensus estimate of $981.25 million. As a group, equities research analysts expect that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.